We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Entasis Therapeutics Holdings Inc. (“Entasis” or the “Company”) (NASDAQ: ETTX) in connection with the proposed acquisition of the Company by Innoviva, Inc. (NASDAQ: INVA) via a tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $2.20 in cash for each share of Entasis common stock owned.  The transaction is valued at approximately $113 million.

Weiss Law is investigating whether (i) Entasis’s board of directors (“Board”) acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $2.20 per-share merger consideration adequately compensates Entasis’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed, including whether INVA, that already owns approximately 60% of outstanding Entasis common stock, improperly coerced the Board to enter into the merger agreement.